The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oscar22.
I appreciate your analysis of IMM's strengths and the excellent prospects the company has of success in the use of the P140 platform in treating two autoimmune diseases, Lupus and CIDP.
Another reason (not mentioned by Oscar) to believe in the wide potential of IMM's peptide's platform, is the strength which the company derives from its exclusive right to commercialise the discoveries of France's principal scientific research institute, CNRS. And so, on its scientific team it has Prof. Sylvane Muller, one of the research directors of CNRS, and inventor of P140.
Eventually, and likely within 2 to 3 years, we can expect a further roll-out of the P140 as an effective treatment of other autoimmune diseases such as asthma, which have huge market potential.
Moreover, IMM's link to the CNRS, may ensure that IMM remains true to its mission to bring to market a wide range of treatments based on the P140 platform and prevent it from becoming an easy prey to large pharma companies with deep pockets.
Returning to Oscar's post, it would be a rash person who would contradict his evident confidence that Lupuzor will get FDA approval to proceed to a Phase 2/3 trial on the basis of its protocol and that the trial has a very good prospect of success.
Over at BRES today, the sp went up. After the placing.
Does happen.
Oscar are you Jabob Rees Mogg lol? I always worry about a placing when people who sound clever start posting
Brilliant-ignore LOADS and that crowd-looking forward to more.
That's all.
Oscar22, As a long term investor, I must commend you on your detailed and insightful analysis of ImmuPharma. Your substantial contribution significantly elevates the quality of discourse on this investment board. It's refreshing to see such in-depth understanding and thoughtfulness shared here, it is disappointing to see so many lousy and ignorant comments in this board like Lambo or Lord's. I'm certain that your analysis will prove invaluable to many, as it provides a comprehensive and engaging overview of ImmuPharma's recent strides and long-term potential. I look forward to more of your contributions. Thank you and GLA! :)
Lordloadsoflolly, your superficial approach to the complex domain of biotech investing becomes quite apparent with each comment you share. It seems you struggle to fully grasp the profound potential held by revolutionary entities such as ImmuPharma. It's unfortunate that this skewed perspective only serves to distort the dialogue. Surely, brevity has its place, but when it mirrors a deficiency of comprehension and foresight, it does a disservice to the conversation. Undoubtedly, laughter is a welcome relief, but in the realm of investing, it is in-depth understanding and detailed analysis that hold the key to success. I implore you to broaden your knowledge base of the sector before resorting to dismissive, surface-level remarks. As this is my final response to you, it is clear that we operate on vastly divergent plains, and my vision evidently extends far beyond yours.
Oscar22
Your somewhat exuberant language adds some charm to your write up.... thanks for your latest update summary
Even I laughed at that post Oscar lol are you the broker doing the placing that’s my worry
Oscar22 - 'fraid I only got as far as this part of your post before I fell off my chair laughing: "ImmuPharma PLC, a distinguished name in the realm of drug discovery and development"
Nice to see we are 1 of only 3 CO got a mention on PRO active FTSE front page today
that's a really good sign IMO, more eyes on us i suppose''
ImmuPharma - up 10% to 3.4p: Shares leapt after the FDA endorsed the company's proposal for a late-stage clinical trial for the treatment of chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disorder.
we could do with Tim giving a new interview on there ? so wort giving it a plug
in the right directon
ATB
In today's exhilarating announcement, ImmuPharma PLC, a distinguished name in the realm of drug discovery and development, has taken a giant leap in its ongoing journey of innovation. The promising progress in its late-stage clinical programme for Chronic Idiopathic Demyelinating Polyneuropathy (CIDP) further cements ImmuPharma's commitment to advancing healthcare, and presents an array of compelling reasons for continuing engagement with this dynamic company.
1. Expansion of the P140 Platform's Scope:
ImmuPharma's P140 peptide platform stands as a testament to its innovative spirit. Already lauded for its effectiveness in addressing Systemic Lupus Erythematosus (SLE), the recent positive feedback from the FDA has extended the platform's applicability to CIDP as well. This broadening of P140's therapeutic reach reinforces the company's ability to navigate new territories in autoimmune and inflammatory diseases.
2. Tapping into a High-Need Market:
ImmuPharma's foray into the CIDP market represents a well-calculated stride into a domain characterised by significant unmet medical needs. With global sales projected to reach an impressive US$2.7bn by 2029, the company's impending Phase 2/3 adaptive clinical trial for CIDP aligns ImmuPharma with a potential growth trajectory that is both meaningful and substantial.
3. Pursuit of Orphan Drug Status:
ImmuPharma's intention to apply for Orphan Drug status alongside the Investigational New Drug (IND) application is a clear signal of its long-term strategic planning. Attaining this status would afford the company seven years of market exclusivity following approval, a valuable opportunity to fully leverage the potential of the CIDP market.
4. Navigating the Regulatory Waters with Ease:
Today's positive guidance from the FDA instils confidence in ImmuPharma's regulatory acumen. It is indicative of a potential smooth sailing through future regulatory processes, which bodes well for the company's ability to expedite its clinical development plans.
5. Stability through a Dual-Therapeutic Approach:
ImmuPharma’s strategic concentration is not singular. The company maintains a strong commitment to its Lupus programme, with a Phase 2/3 clinical trial for Lupus patients also scheduled to commence in H2 2023. This concurrent advancement in two crucial therapeutic areas imbues the company, and those closely engaged with it, with a sense of stability often elusive in the biotechnology sector.
In sum, ImmuPharma's recent progress demonstrates its robust potential for growth and resilience. The company’s diverse therapeutic portfolio, underscored by positive regulatory feedback and a clear strategic vision, provides ample reasons for sustained engagement. ImmuPharma’s unfolding narrative promises to be a journey of relentless innovation and steadfast commitment to improving patient care.
Disclaimer: This is a personal perspective, not investment advice. Please consult a financial
I fear my 5p by the close somewhat over enthusiastic. That said I do see this as the start of a positive new flow.
Erm, having no cash would be a fairly major business risk lambo! Interesting that commencement of the Phase2/3 trial is: "defined as the CRO is chosen, trial sites are being confirmed and set-up and regulatory and ethics committee submissions are progressing". As we already knew, this is still VERY early days & a real long shot (though potentially transformative for IMM still)
Here we go lol, main risk is IMM have no cash I don’t see any other risks short term
Lambo222 - "buy at 2.6 and sell to others much higher". So the question now is, how much higher before we suddenly see lambo222 posting about all the negatives & risks inherent in holding IMM?
You put your right arm in
Your right arm out
In, out, in, out
You shake it all about
In that case take the placing of it comes, obviously depends on the price
Positive news was expected by all but Lambo222 we are still a long way from your 10p projection but we still have a few weeks to go :-(.
.....
yes...you guessed.....
...a Placing and Open Offer. Hope I am wrong but the cupboard is devoid of shekels!
Your right Pokerchips the news was expected and that’s why it was such an easy trade, buy at 2.6 and sell to others much higher it’s not rocket science, given it was a PRE IND meeting it was impossible for them to reject anything so was a risk free trade
FDA supports the underlying science and mechanism of action of P140 across several auto-immune/inflammatory diseases and is a significant breakthrough for the P140 platform.
Got to go much much higher now.
Your a little sheep, I loaded at 2.6p like many others and today is Xmas day, easy money
The positive response was expected , as well as the next stage to now submit the application ...but..it certainly is surprising to receive a RNS so quickly after the meeting.... someone must have pushed Tim to get it out there fast and create some sense of momentum....
I think even Lambo is surprised the RNS appeared so soon
Seem delusional ,its done nothing for c 9 months ,been under 4p and mostly under 2.60 for majority of the time ,check here
https://invst.ly/103w88
Oh dear me, you are a boastful arrogant little person. People like you make these boards toxic. Shame.
As I said before a Nolupus and other keep making smart comments while actual smart people make money…. They are called cowards, I’d love nothing more than to take their money shame they won’t take my bets